###### What\'s new?

A mathematical model of the human cardiac ventricles embedded in a torso is used to simulate the effect of multiple ion channel block on the electrical activity of the heart from ion channel to electrocardiogram.L-type calcium block results in QT interval shortening, ST elevation, and T-wave amplitude reduction, caused by decrease in action potential duration and action potential amplitude and in dispersion of repolarization.When L-type calcium current (*I*~CaL~) and rapidly activating potassium current (*I*~Kr~) blocks are simultaneously applied, QT interval is more sensitive to the degree of *I*~CaL~ block whereas T-wave amplitude is mostly determined by *I*~Kr~ block.

Introduction {#s1}
============

Calcium (Ca^2+^) is the ionic link in cardiac excitation--contraction coupling, which, in cardiac cells, starts following the upstroke of the action potential (AP) and causes the opening of the L-type voltage-dependent Ca^2+^ channels. These ion channels are expressed by the CACNA1C gene. L-type Ca^2+^ channels constitute one of the most important Ca^2+^ entry pathways into the cell and have been classified by their sensitivity to dihydropyridine-based compounds (e.g. nifedipine). Different compounds have been developed to target calcium channels and in particular L-type calcium channels. The compounds aim to modulate the cardiac ventricular L-type Ca^2+^ current (*I*~CaL~). These agents have been classified to three main classes: phenylalkylamines (e.g. verapamil), benzothiazepines (e.g. diltiazem), and dihydropyridines (e.g. nifedipine).^[@EUU122C1]^ Calcium channel blockers have wide clinical applicability and they are used to decrease blood pressure in patients with hypertension. Calcium channel blockers are also frequently used to alter heart rate, to prevent cerebral vasospasm, and to reduce chest pain caused by angina pectoris. However, it has been shown that they could increase the mortality rate in elderly patients, and have been known to have multiple side effects.^[@EUU122C2],[@EUU122C3]^ They have also been associated with a risk of cancer.^[@EUU122C4]^ Abnormalities in *I*~CaL~, in particular, have also been linked to ventricular arrhythmias, impaired excitation--contraction coupling leading to heart failure, as well as atrial fibrillation.^[@EUU122C5]^ These abnormalities could be related to cardiac diseases or to drug-induced side effects. In both cases, they result in ionic currents abnormalities, which cause alterations in both ventricular depolarization and repolarization properties.

Of particular concern are changes in ventricular repolarization caused by combined *I*~CaL~ and rapidly activating potassium current (*I*~Kr~) alterations, which can manifest themselves as changes in the QT interval and T-wave of the electrocardiogram (ECG), and have been linked to increased risk of arrhythmic death. QT prolongation is considered an indicator of increased risk of torsades de pointes and can lead to the abandonment of the compound development. However, some QT prolonging drugs present no arrhythmic episodes and some others are known to be useful antiarrhythmic drugs for most patients. Interpretation of drug-induced effects on the ECG is however challenging due to the variability of cardiac substrates and also to the frequent multichannel action of most compounds.^[@EUU122C6]--[@EUU122C9]^ Therefore, a better understanding of drug-induced changes in the ECG and how they relate to ionic mechanisms and arrhythmic risk is needed.

Recent reviews have highlighted how computational modelling and simulation can help in the investigation of arrhythmias and antiarrhythmic therapy.^[@EUU122C10]--[@EUU122C13]^ Recent studies have specifically shown the usefulness of whole-ventricular computer simulations to investigate drug effects on the electrical activity of the heart.^[@EUU122C9],[@EUU122C14]--[@EUU122C16]^ In this study, we aim at using a multiscale computational human torso model to investigate and quantify the combined effect of *I*~CaL~ and *I*~Kr~ block on human ventricular activity from the ionic to the ECG level.

Methods {#s2}
=======

Human multiscale torso--heart model {#s2a}
-----------------------------------

A human model of the cardiac ventricles embedded in a torso is used and illustrated in *Figure [1](#EUU122F1){ref-type="fig"}A* and *B*. The human ventricular model includes realistic representation of human ventricular kinetics, anatomy, and fibre orientation as previously described in Zemzemi *et al*.^[@EUU122C15]^ Briefly, the anatomical model is based on data presented in Chapelle *et al*.^[@EUU122C17]^ and the computational mesh contains 2 401 151 vertices and 14 336 528 tetrahedral elements.^[@EUU122C15]^ The Ten Tusscher and Panfilov human AP model^[@EUU122C18]^ is used to represent human membrane kinetics throughout the myocardium, including epicardial, endocardial, and mid-myocardial ionic properties based on transmural location. Therefore, transmural heterogeneity in the human AP was introduced in our human ventricular model, in agreement with previous studies such as Okada *et al*.^[@EUU122C19]^ Figure 1(*A*) A cross-section of the human ventricles showing the activation times map transmurally and on the endocardium. (*B*) Distribution of the body surface potential (right) for the IC~50~ *I*~CaL~ block dose in a snapshot taken during the repolarization phase. (*C*) Simulated effect of different doses (control, 1× IC~50~, 2× IC~50~, 10× IC~50~, 30× IC~50~) of *I*~CaL~ blocker on a representative ventricular AP at a point located at the base of the ventricles. *X*-axis time (ms). *Y*-axis potential (mV). (*D--H*) Simulated effect of combined *I*~CaL~ and *I*~Kr~ blockers on the second lead of the ECG. Drug dose is 0× IC~50~, 1× IC~50~, 2× IC~50~, 10× IC~50~, and 30× IC~50~ for *I*~Kr~ blocker in Panels *D*--*H*, respectively, and in each panel a different dose of *I*~CaL~ block is shown with a different colour as shown in the legend. *X*-axis shows time in ms, *Y*-axis potential in mV

The human ventricular model is coupled to the diffusion equation in the torso to take into account the propagation of the electrical wave from heart to torso to compute the ECGs on the body surface.^[@EUU122C15],[@EUU122C20]^

To simulate sinus rhythm activation, a time-dependent stimulus of 0.5 ms duration and 100 mA cm^−3^ strength is applied to the endocardium. To mimic Purkinje network activation, the endocardium surface is then progressively activated from apex to base to produce a simulated activation sequence illustrated in *Figure [1](#EUU122F1){ref-type="fig"}A*, in line with the experimental results by Durrer *et al*.^[@EUU122C21]^

Drug/ion channel interaction model {#s2b}
----------------------------------

The human AP model^[@EUU122C18]^ was modified to enable simulation of drug action on *I*~CaL~ and *I*~Kr~ using the simple pore block model^[@EUU122C7],[@EUU122C15],[@EUU122C22]^. The degree of channel block is a function of drug concentration and the drug half maximal inhibitory concentration (IC~50~) value for the targeted ionic channel. Thus, for a given drug dose \[*D*\] and IC~50~ value with respect to the channel *j* the formulation of drug action on the ionic current conductance *g~j~* is given by:$$g_{j}(\lbrack D\rbrack) = g_{j}\left( \frac{1}{1 + \left( \frac{\lbrack D\rbrack}{\text{IC}_{50}} \right)^{n}} \right)$$ with Hill coefficient *n* = 1.

Computational methods and data analysis {#s2c}
---------------------------------------

All the simulations in this paper have been conducted using the software CHASTE (Cancer Heart and Soft Tissue Environment).^[@EUU122C23],[@EUU122C24]^ Details of models and numerical methods are as described in the supplementary material in Zemzemi *et al*.^[@EUU122C15]^ Simulations were run in the Bordeaux federative platform for research in computer sciences and mathematics called PLAFRIM (<https://plafrim.bordeaux.inria.fr/>).

We compute the standard 12-lead ECG by extracting the electrical potential values at the standard 9 electrode locations on the body surface of the human torso model.^[@EUU122C15]^ A snapshot of the distribution of the electrical potential on the body surface from which the ECG is obtained is represented in *Figure [1](#EUU122F1){ref-type="fig"}B*. In the results of this study, all the ECG-based biomarkers are quantified for the second Einthoven lead of the ECG. The QT interval is computed as the time interval between the Q- and the T-wave peak of the ECG. At each ventricular node, the the action potential duration at 90% (APD~90~) is computed as the time interval between the depolarization time and the time at which the transmembrane potential is 90% repolarized. Electrophysiological alterations caused by ionic current block are also described by analysing APD~90~ and AP morphology in one selected node located at the base of the left ventricle. Previous studies have linked changes in T-wave amplitude with the Wilson ventricular gradient, which is the gradient of the transmembrane potential in the ventricles.^[@EUU122C25],[@EUU122C26]^ As in references,^[@EUU122C27]--[@EUU122C29]^ we therefore quantified the Wilson ventricular gradient by computing the spatial dispersion of ventricular repolarization. To do so, the spatial dispersion of transmembrane potential throughout the human ventricles is calculated at each time step during the simulations, as the voltage difference between the maximal and minimal values of the transmembrane potential throughout the ventricles at each time step. Its maximum value over time during the repolarization phase is quantified and referred to in the paper as the maximum (spatial) dispersion of transmembrane potential, for each simulation.

Results {#s3}
=======

The human whole-ventricular model embedded in the torso (*Figure [1](#EUU122F1){ref-type="fig"}A* and *B*) was used to simulate the effect of *I*~CaL~ and *I*~Kr~ blocks on ventricular electrophysiology and the ECG. *Figure [1](#EUU122F1){ref-type="fig"}C* shows the simulated effect of *I*~CaL~ block on the AP for blocker dose \[*D*\] increasing from zero (control) to \[*D*\] = IC~50~, 2× IC~50~, 10× IC~50~, and 30× IC~50~ (corresponding to 50, 66, 90, and 96% of *I*~CaL~ block, respectively). Increasing *I*~CaL~ blocker dose results in decrease in AP amplitude and shortening of APD~90~. Indeed APD~90~ shortens from 290 ms in control to 242, 219, 150, and 126 ms for *I*~CaL~ block dose of \[*D*\] = IC~50~, 2× IC~50~, 10× IC~50~, 30× IC~50~, respectively. The effect of *I*~Kr~ block was shown in our previous work,^[@EUU122C15]^ and as expected, it leads to a progressive prolongation of the APD~90~ from 290 ms in control conditions to 312 ms for IC~50~ *I*~Kr~ block, and to 320, 334, and 337 ms) for 2× IC~50~, 10× IC~50~, and 30× IC~50~ *I*~Kr~ block dose, respectively. This corresponds to APD~90~ prolongation by 7.5, 10, 15, and 16% for IC~50~, 2× IC~50~, 10× IC~50~, and 30× IC~50~ *I*~Kr~ block dose, respectively.

Drugs often exhibit multichannel action and therefore their effects on the heart are difficult to interpret. This is especially the case, when the ion channels affected by the drug have counteracting effects on cardiac behaviour such as *I*~CaL~ and *I*~Kr~, inward and outward currents, respectively, and both important during the plateau and repolarization phases of the human ventricular AP. Therefore, simulations using the human torso model were conducted to investigate the effect of combined *I*~CaL~ and *I*~Kr~ blocks on the ECG for 25 different dose combinations. *Figure [1](#EUU122F1){ref-type="fig"}D*--*H* displays ECG traces obtained for five *I*~CaL~ block doses, for no *I*~Kr~ block (e.g. control, *Figure [1](#EUU122F1){ref-type="fig"}D*), and IC~50~, 2× IC~50~, 10× IC~50~, 30× IC~50~ doses of *I*~Kr~ blocker (*Figure [1](#EUU122F1){ref-type="fig"}E*--*H*, respectively).

For all *I*~Kr~ blocker doses, the most notable effects of increasing *I*~CaL~ block in the ECG are a progressive shortening of the QT interval and simultaneous elevation of the ST segment with increasing dose. Indeed, the QT interval decreases from 315 ms in control to 265 ms (by 15%) for *I*~CaL~ block dose of IC~50~, to 240 ms (by 23%) for 2× IC~50~, to 176 ms (by 44%) for 10× IC~50~ dose, and to 157 ms (by 57%) for *I*~CaL~ block dose of 30× IC~50~. The ECG changes caused by *I*~CaL~ block in *Figure [1](#EUU122F1){ref-type="fig"}D--H*, and specifically the QT shortening, are explained by the AP changes shown in *Figure [1](#EUU122F1){ref-type="fig"}C*, and in particular the decrease in both APD and plateau levels caused by the reduced *I*~CaL~ as blocker dose is increased. Our simulation results also show that when *I*~Kr~ block is added to *I*~CaL~ block, QT shortening still occurs but becomes milder due to the APD~90~ prolongation effects of *I*~Kr~ block. In addition, increasing *I*~Kr~ block results in significant decrease in T-wave peak for all *I*~CaL~ blocker doses, as shown when comparing *Figure [1](#EUU122F1){ref-type="fig"}D--H*.

The simulated effects of combined *I*~CaL~ and *I*~Kr~ blocks on the human ECG are further illustrated and examined in *Figure [2](#EUU122F2){ref-type="fig"}*. The second lead of the ECG is shown in *Figure [2](#EUU122F2){ref-type="fig"}A* superimposed for different combinations of IC~50~ and 2× IC~50~ block. As previously shown in *Figure [1](#EUU122F1){ref-type="fig"}*, selective *I*~Kr~ block prolongs the QT whereas selective *I*~CaL~ block shortens it, in line with their respective effects on the APD of human ventricular myocytes. In both cases, the T-wave amplitude decreases, in a larger amount for *I*~Kr~ than for *I*~CaL~ block (as shown in *Figure [1](#EUU122F1){ref-type="fig"}D--H*). Combined *I*~Kr~ and *I*~CaL~ blocks result in more moderate changes in QT than single channel block due to the counteracting effects of the two current blocks on the APD. Furthermore, *Figure [2](#EUU122F2){ref-type="fig"}A* shows that *I*~Kr~ block does not affect the QRS interval, whereas *I*~CaL~ block slightly widens it, due to a very small slowing of the conduction velocity. Figure 2(*A*) Effect of different combinations of *I*~Kr~ and *I*~CaL~ blocks doses (0× IC~50~, 1× IC~50~, 2× IC~50~) on the second lead of the ECG. *X*-axis time (ms). *Y*-axis potential (mV). (*B*) Effect of different combinations of *I*~Kr~ (0× IC~50~, 1× IC~50~, 2× IC~50~) from left to right and *I*~CaL~ (0× IC~50~, 1× IC~50~, 2× IC~50~) from top to bottom on the APD~90~ distribution. Colour bar in millisecond.

*Figure [2](#EUU122F2){ref-type="fig"}B* illustrates the simulated effect of simultaneous *I*~CaL~ and *I*~Kr~ block on the distribution of APD~90~ values in a transmural cross-section of the human ventricular model used in the simulations. The panels in *Figure [2](#EUU122F2){ref-type="fig"}B* correspond to increasing *I*~CaL~ block from top to bottom and to increasing *I*~Kr~ block from left to right. As expected, the simulations show that overall APD~90~ shortens with increasing *I*~CaL~ blocker dose, whereas it is prolonged when increasing *I*~Kr~ block dose. Combined block results in moderate APD~90~ shortening throughout the ventricles, which explains the moderate QT shortening seen in *Figure [2](#EUU122F2){ref-type="fig"}A*. In all cases, the epicardial surface shows shorter APD values than mid-myocardial and endocardial tissue resulting in transmural dispersion in APD~90~. The APD maps also show how dispersion in APD~90~ is modulated by different degrees of *I*~CaL~ and *I*~Kr~ blocks (*Figure [2](#EUU122F2){ref-type="fig"}B*).

*Figure [3](#EUU122F3){ref-type="fig"}* shows a quantification of the APD~90~ in a selected node at the base of the ventricles (*Figure [3](#EUU122F3){ref-type="fig"}A*), QT interval (*Figure [3](#EUU122F3){ref-type="fig"}B*), and maximum spatial dispersion of transmembrane potential (*Figure [3](#EUU122F3){ref-type="fig"}C*) for the 25 combined doses of *I*~CaL~ and *I*~Kr~ blocks considered in the simulations. *Figure [3](#EUU122F3){ref-type="fig"}A* provides further quantification of the fact that combined *I*~CaL~ and *I*~Kr~ blocks at similar doses (diagonal of *Figure [2](#EUU122F2){ref-type="fig"}B*) results in APD~90~ shortening by 23 and 40 ms for IC~50~ and 2× IC~50~ doses for both currents, respectively. Simulation results therefore reflect the fact that APD~90~ using our human model is more sensitive to *I*~CaL~ block than to *I*~Kr~ block for a similar drug dose with respect to the IC~50~. This is also reflected in the QT interval, quantified for the 25 simulations in *Figure [3](#EUU122F3){ref-type="fig"}B*. Therefore, as for APD~90~, the effect of *I*~CaL~ block on reducing the QT interval is more pronounced than the prolongation caused by *I*~Kr~ block for the same degree of block. Figure 3Effect of combining doses of L-type calcium and hERG blockers (control, 1× IC~50~, 2× IC~50~, 10× IC~50~, 30× IC~50~) on the QT interval (units are mV, ms, and ms, respectively) (*A*), on the APD~90~ (*B*), and on the maximum dispersion of the transmembrane potential during the repolarization phase (*C*). The APD~90~ is computed from a point located at the base of the left ventricle.

As shown in *Figures [1](#EUU122F1){ref-type="fig"}* and *[2](#EUU122F2){ref-type="fig"}*, the decrease in the T-wave amplitude is more pronounced for *I*~Kr~ than for *I*~CaL~ block. It decreases from 0.72 mV in control to 0.68 and 0.64 mV for IC~50~ and 2× IC~50~ dose of *I*~CaL~ blocker, whereas it decreases from 0.72 mV to 0.48 and 0.39 mV) for IC~50~ and 2× IC~50~ dose of *I*~Kr~ blocker. Alterations in the T-wave amplitude in our simulations are complex and affected by heterogeneous changes in AP morphology and duration. Our results show that they could be explained, at least in part, by alterations in the maximum dispersion of transmembrane potential, which result from the changes in heterogeneity in APD~90~ illustrated in *Figure [2](#EUU122F2){ref-type="fig"}B*. As shown in the histograms in *Figure [3](#EUU122F3){ref-type="fig"}C*, both *I*~CaL~ and *I*~Kr~ blockers result in maximum spatial dispersion of transmembrane potential below its value in control. The decrease in maximum dispersion caused by *I*~Kr~ block is more pronounced than the decrease caused by *I*~CaL~ block for similar doses. This is in line with the decrease in T-wave peak shown in the ECG in *Figure [1](#EUU122F1){ref-type="fig"}D--H*.

*Figure [3](#EUU122F3){ref-type="fig"}C* also shows that the maximum spatial dispersion of transmembrane potential decreases with increasing *I*~CaL~ block dose up to 10× IC~50~. Further increase in *I*~CaL~ block dose results in a trend inversion: the maximum dispersion of transmembrane potential is higher for 30× IC~50~ than for 10× IC~50~ (but still smaller than in control). This could be explained by the fact that for 30× IC~50~ *I*~CaL~ block dose, the AP repolarization phase becomes very sharp, as illustrated in *Figure [1](#EUU122F1){ref-type="fig"}C*. Sharp repolarization phases of the AP result in large spatial gradients in transmembrane potential throughout the human ventricles. As shown in *Figure [1](#EUU122F1){ref-type="fig"}E--H*, the increased transmembrane potential gradient also results in higher values of the T-wave peak in the ECG, for 30× IC~50~ than for 10× IC~50~ *I*~CaL~ block dose.

Discussion {#s4}
==========

In this work, we have shown the ability of computer simulations to provide insights into the effect of multiaction ion channel blockers on the electrical activity of the human heart and its reflection on the body surface ECG. This is possible through the use of a multiscale human torso--heart anatomical model with biophysically detailed representation of human ventricular membrane dynamics, fibre orientation, and electrophysiological heterogeneity. Our study extends our previous work showing the effect of potassium and sodium channel block on the ECG.^[@EUU122C15],[@EUU122C16]^ Here, we focus on investigating the manifestation of the simultaneous block of the inward *I*~CaL~ and the outward *I*~Kr~ on human whole-ventricular activity, which has opposite effects on cardiac repolarization and therefore presents a challenge in the interpretation of the ECGs.

Our results show that *I*~CaL~ block results in shortening of the QT interval, reduction of T-wave amplitude, elevation of the ST segment, and slight widening of the QRS complex. The changes in the ECG are explained by the shortening of APD, reduction of AP amplitude during the plateau phase, decrease of maximum dispersion of the transmembrane potential, and a slight reduction in conduction velocity.

Clinical data on the effect of calcium blockers on the ECG have mostly focused on their effect on the atria and the atrioventricular node,^[@EUU122C30],[@EUU122C31]^ rather than in the human ventricles and the ECG, and often in combination with other drugs. Our simulation results are however in agreement with experimental studies reporting APD and QT shortening caused by verapamil in feline wedge preparations.^[@EUU122C32]^ Furthermore, the QT interval shortening and the ST segment elevation in human have also been linked to L-type calcium channel function. Thus, Antzelevitch *et al*.^[@EUU122C33]^ reported that gene mutations mainly in CACNA1C and CACNB2 result in loss of *I*~CaL~ function and cause a QT shortening and ST elevation, as reported in our simulations. It has also been reported in Proano *et al*.^[@EUU122C34]^ that overdoses of calcium blockers come with abnormalities in T-wave and ST segment. These abnormalities could be seen in our simulation in *Figure [1](#EUU122F1){ref-type="fig"}D* and *E* for high doses of L-type calcium block (e.g. 10× IC~50~ and 30× IC~50~).

Our theoretical investigation aims at providing new insights, which could be valuable for ECG interpretation. The combined action of *I*~CaL~ and *I*~Kr~ blocks investigated in our study is particularly interesting as the two currents have opposite effects on cardiac repolarization and therefore lead to complex and counteracting changes in ECG biomarkers with difficult interpretation. Our results show that the main effect of *I*~CaL~ block on the ECG is QT shortening and slight ST elevation, whereas *I*~Kr~ block results in QT prolongation and T-wave peak reduction. The simultaneous application of *I*~Kr~ and *I*~CaL~ blocks in doses from IC~50~ to 30× IC~50~ block results in overall decrease in APD and QT interval, which means that for a similar IC~50~/dose relationship, the effect of *I*~CaL~ block on the APD and QT interval is more pronounced than *I*~Kr~ block in our human model.

Importantly, our simulations show that *I*~Kr~ block effects are more important in determining the T-wave amplitude than *I*~CaL~ block. Moreover for high doses of *I*~Kr~ block, our study shows that there is a critical dose of *I*~CaL~ block, in this case 10× IC~50~, in the regulation of T-wave peak: lower *I*~CaL~ blocker doses reduce the T-wave amplitude and higher doses, increases the T-wave amplitude. Our results suggest that the maximum spatial dispersion in transmembrane potential during the repolarization phase plays an important role in this modulation, as suggested by results shown in (*Figure [3](#EUU122F3){ref-type="fig"}C*).

A strong correlation is seen between changes in APD and QT interval caused by both *I*~Kr~ and *I*~CaL~ blocks and also by their combination. This is mainly due to the fact that both of *I*~Kr~ and *I*~CaL~ blockers affect the repolarization phase, and have negligible effects during the depolarization of the AP, as shown in our simulations. Therefore, *I*~Kr~ and *I*~CaL~ blockers also have negligible effects on conduction velocity, activation patterns under sinus rhythm and therefore the QRS complex is not affected (*Figures [1](#EUU122F1){ref-type="fig"}* and *[2](#EUU122F2){ref-type="fig"}*). The QT interval is therefore mostly affected by changes in APD. In the presence of sodium blockers however, as considered in our previous study,^[@EUU122C15]^ increasing drug dose results in changes in activation sequence and a prolongation of the QRS and QT interval durations, without any significant effects on the APD. Therefore, the QT interval prolongation caused in the presence of sodium block is not solely correlated with APD.

The human torso--heart model presented in our study could be used to simulate additional drug effects, and our results could be of value to guide the evaluation and interpretation of ECG data obtained following application of Class III and Class IV blockers exhibiting multichannel action.^[@EUU122C35],[@EUU122C36]^ Future work could also extend our work to include inter-subject variability in anatomy and electrophysiology^[@EUU122C37],[@EUU122C38]^ and by extending the simple pore block drug model to more comprehensive models of drug/ion channel interactions, especially when arrhythmic mechanisms are investigated.^[@EUU122C11],[@EUU122C22],[@EUU122C39]^ Furthermore, the human whole-ventricular model includes transmural heterogeneities in ionic currents but neglects the potential contribution of apex--base and left-to-right heterogeneities.^[@EUU122C40],[@EUU122C41]^ The simulation study by Okada *et al*.^[@EUU122C19]^ shows however that the presence of transmural heterogeneities is sufficient to produce ECGs with the right polarity of the T-wave, whereas apex-to-base heterogeneities need to be very large to produce an effect on the ECG. We therefore believe that apex-to-base and left-to-right heterogeneities as measured in the *in vivo* human ventricles are likely to produce a small modulation of the results presented in this study and could be the focus of future investigations.

Conclusion {#s5}
==========

In this study, we present a simulation study of the effect of ion channel block on the electrical activity of the heart from drug/ion channel interactions to the ECG. The human bidomain model of the heart embedded in a torso allows for ECG simulations to be conducted with realistic representation of human anatomy and electrophysiological function, and could be used for further investigations including specific drug effects or disease conditions. We show how *I*~CaL~ block reduces the APD and the AP amplitude during the plateau phase, which, in the ECG, results in ST elevation, QT interval shortening, and slight T-wave amplitude reduction. As drugs often exhibit multiple channel effects, we evaluated the simultaneous effect of *I*~CaL~ and *I*~Kr~ on human cardiac activity. As expected, *I*~CaL~ and *I*~Kr~ blocks have opposite effects on the QT interval of the ECG: *I*~CaL~ reduces the QT interval whereas *I*~Kr~ prolongs it. However, QT interval is more sensitivity to *I*~CaL~ block, and therefore combined block results in QT shortening. On the contrary, T-wave amplitude is mostly determined by *I*~Kr~ block dose, even though both *I*~CaL~ and *I*~Kr~ decrease T-wave peak. Our simulations show that modulation of the T-wave peak in most cases reflects changes in the maximum spatial dispersion of transmembrane potential. Finally, our study illustrates how the multiscale nature of our human torso/heart model allows for the assessment of the consequences of drug-induced ionic changes on the AP at the cell level, on the APD distribution throughout the ventricles, activation and repolarization maps at the organ level, and on the ECG at the body surface level. Both the human model and the insights provided by the simulation study could contribute to a better characterization of drug-induced effects on the heart for pre-clinical drug testing and also to unravel the ionic basis of new biomarkers of predicting drugs cardiotoxicity.
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